NCT03682289 - Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 17, 2019

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2028

Conditions

Clear Cell Renal Cell CarcinomaLocally Advanced Pancreatic CancerLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid NeoplasmMetastatic Renal Cell CarcinomaMetastatic Urothelial CarcinomaMetastatic Pancreatic CancerStage III Pancreatic CancerStage III Renal Cell CancerStage IV Pancreatic CancerStage IV Renal Cell CancerEndometrial CancerMetastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Ceralasertib

Given orally

DRUG

Olaparib

Given orally

DRUG

Durvalumab

Given intravenously (IV)

Trial Locations (3)

60637

RECRUITING

University of Chicago Comprehensive Cancer Center, Chicago

91010

RECRUITING

City of Hope Comprehensive Cancer Center, Duarte

94143

RECRUITING

University of California, San Francisco, San Francisco